Clinical Trials Browser

Phase 2 × EGFR Positive Non-small Cell Lung Cancer × 90 days × Clear all

NCT07322783 2026-01-07

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Phase 2 Recruiting

EGFR Positive Non-small Cell Lung Cancer